• From Epigenetic Silence to Translational Strategy in OS

  2026-09-20

  A thought-leadership analysis of how RUNX2-driven chromatin repression limits interferon signaling and immune checkpoint blockade in osteosarcoma, with practical guidance for validating the pathway and responsibly exploring Repaglinide in a separate metabolic-context arm.

• Trichostatin A: From HDAC Inhibition to Tumor Immunity

  2026-09-19

  Trichostatin A (TSA) is more than a proliferation tool: it can help dissect how HDAC-dependent chromatin states influence tumor immunogenicity. This article connects TSA assay design with the CBX2–RACK1–HDAC1 pathway and highlights practical controls, readouts, and limitations.

• RHEB Neddylation Activates mTORC1 in Liver Cancer

  2026-09-18

  The reference study identifies RHEB as a non-cullin substrate of the UBE2F-SAG neddylation machinery and maps the modification to lysine 169. By connecting RHEB neddylation with lysosomal localization, GTP binding, mTORC1 activity, and PTEN-loss-driven liver tumorigenesis, the work expands the functional scope of neddylation beyond cullin regulation.

• 25-Hydroxycholesterol Reprograms Tumor Macrophages

  2026-09-18

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that reinforces suppressive tumor-associated macrophage states. Their work connects lysosomal lipid handling to the GPR155–mTORC1–AMPKα–STAT6 pathway and shows how CH25H targeting can improve T-cell surveillance and anti-PD-1 responses.

• Lyso-Tracker Red for Nanovaccine Trafficking

  2026-09-17

  Use Lyso-Tracker Red to convert nanovaccine trafficking into a measurable live-cell readout of acidic-compartment entry, retention, and apparent escape. This workflow complements immune-endpoint assays by connecting CLam/OVA particle design with dendritic-cell localization and lysosomal behavior.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Uses

  2026-09-17

  This dual-fluorescence reporter separates mRNA uptake from functional translation in one experiment. It enables quantitative nanoparticle validation, macrophage-delivery screening, trafficking studies, and faster optimization of gene-delivery workflows.

• Trifluoperazine 2HCl: From D2 to Host Defense

  2026-09-16

  Trifluoperazine 2HCl offers translational researchers a high-affinity dopamine D2 receptor probe for connecting dopaminergic signaling pathway modulation with emerging host-directed antibacterial research. This article examines the mechanistic rationale, experimental controls, evidence boundaries, and strategic opportunities for using the compound across neuropharmacology, immunology, and cancer-related models.

• GW 4869 (hydrochloride hydrate) for Reliable Assays

  2026-09-16

  Learn how GW 4869 (hydrochloride hydrate), SKU C4769, can support controlled studies of neutral sphingomyelinase, ceramide signaling, extracellular-vesicle release, and cell injury. This scenario-based guide connects formulation details with practical viability-assay controls and evidence from lupus nephritis research.

• FOLR3 Amplifies TGFβ Signaling in NASH Fibrosis

  2026-09-15

  This preprint identifies secreted folate receptor-gamma (FOLR3) as a human-associated driver of fibrogenesis in nonalcoholic steatohepatitis, linking its interaction with HTRA1 to enhanced TGFβ signaling in hepatic stellate cells. The findings suggest that FOLR3 may be both a fibrosis-associated biomarker and a mechanistic target, although species differences and the preprint status require careful interpretation.

• Calpeptin: Calpain Inhibitor for Fibrosis Research

  2026-09-15

  Calpeptin is a nanomolar calpain inhibitor with a reported IC50 of 5 nM for human calpain 1. Evidence supports its use in calpain, extracellular-vesicle, pulmonary fibrosis research, and fibrosis and inflammation modulation, but biochemical potency must not be treated as a universal cellular dose.

• 3X (DYKDDDDK) Peptide: From Tag to Assay Control

  2026-09-14

  The 3X (DYKDDDDK) Peptide is more than an epitope label: it can serve as a control element for purification, immunodetection, structural biology, and metal-sensitive assays. This article connects its assay utility with mechanistic lessons from nimbolide chemoproteomics and targeted protein degradation.

• In Vitro Drug Response Evaluation in Cancer

  2026-09-14

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to separate growth inhibition from actual cancer-cell killing. This methodological framework improves interpretation of drug-response assays and provides a more rigorous basis for evaluating DNA repair–targeted agents in translational cancer research.

• Epacadostat (INCB024360) Whole-Blood Assays

  2026-09-13

  Epacadostat (INCB024360) connects nanomolar IDO1 inhibition with practical whole-blood cytokine, kynurenine, and T-cell function assays. This workflow guide shows how to separate direct enzymatic effects from donor, matrix, and checkpoint-combination variables in immuno-oncology research.

• Trametinib Resistance Biology: Designing Better Assays

  2026-09-12

  Trametinib and GSK1120212 enable precise MEK1/2 inhibition, but endpoint viability alone can conceal adaptive resistance. This guide translates multi-omics findings into resistance-aware assay design, pathway readouts, and practical oncology research workflows.

• Fingolimod (FTY720) for T-Cell Trafficking Assays

  2026-09-11

  Fingolimod (FTY720) offers a controlled way to perturb S1P-dependent lymphocyte distribution while researchers evaluate magnetic, antibody-guided T-cell engineering. This practical guide separates established MS and neurobiology evidence from exploratory tumor-immunology applications, with workflow parameters and troubleshooting safeguards.

8065 records 1/538 page Next 12345 下5页 Last page